Keyphrases
Acute Leukemia
22%
Acute Lymphoblastic Leukemia
21%
Acute Myeloid Leukemia
60%
Aggressive non-Hodgkin Lymphoma
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Anti-CD19 chimeric Antigen Receptor T Cells
25%
Bendamustine
24%
Bone Marrow
22%
CD19 chimeric Antigen Receptor T Cells
21%
Chemotherapy
28%
Chimeric Antigen Receptor T Cells (CAR-T)
59%
Chimeric Antigen Receptor T-cell Therapy
38%
Chronic Lymphocytic Leukemia
25%
Complete Remission
24%
Complete Response
18%
Confidence Interval
45%
Cyclophosphamide
15%
Diffuse Large B-cell Lymphoma (DLBCL)
22%
Engraftment
18%
Follicular Lymphoma
15%
Graft-versus-host Disease (GvHD)
17%
Hazard Ratio
29%
Helios
18%
High Risk
19%
High-dose Chemotherapy
17%
Hodgkin Lymphoma
21%
Ibrutinib
22%
Leukemia
16%
Leukemia Patients
52%
Leukocytes
16%
Lymphoma
17%
Lymphoma Patients
28%
Multiple Myeloma
35%
Multiple Myeloma Patients
15%
Multivariate Analysis
16%
Non-Hodgkin Lymphoma
28%
Overall Response Rate
15%
Overall Survival
55%
Phase II Study
19%
Point-of-care
19%
Positron Emission Tomography-computed Tomography (PET-CT)
44%
Progression-free Survival
37%
Reduced-intensity Conditioning
27%
Relapsed or Refractory
60%
Relapsed or Refractory Acute Myeloid Leukemia
38%
Rituximab
47%
Salvage Therapy
23%
Stem Cell Transplantation
29%
Stromal Cell-derived factor-1 (SDF-1)
17%
Transplantation
21%
Medicine and Dentistry
Acute Leukemia
13%
Acute Lymphoblastic Leukemia
30%
Acute Myeloid Leukemia
52%
Adriamycin Bleomycin Vinblastine Dacarbazine
14%
Adverse Event
13%
Allogeneic Hematopoietic Stem Cell Transplantation
24%
Allogeneic Stem Cell Transplantation
27%
Autologous Stem Cell Transplantation
27%
B Cell
15%
B-Cell Chronic Lymphocytic Leukemia
16%
B-Cell Lymphoma
23%
BEACOPP
12%
Bendamustine
20%
Cancer
14%
Chimeric Antigen Receptor
19%
Chimeric Antigen Receptor T-Cell
64%
Chimeric Antigen Receptor T-Cell Immunotherapy
30%
Computer Assisted Tomography
13%
Conditioning
12%
Cyclophosphamide
15%
Diffuse Large B-Cell Lymphoma
20%
Diseases
67%
Drug Megadose
15%
Fluorine-18
13%
Follicular Lymphoma
16%
Hazard Ratio
22%
Hematopoietic Cell
13%
Hematopoietic Stem Cell Transplantation
18%
High Dose Chemotherapy
16%
Hodgkin's Lymphoma
45%
Ibritumomab Tiuxetan
13%
Ibrutinib
18%
Induction Chemotherapy
14%
Large-Cell Lymphoma
20%
Lymphocytic Lymphoma
13%
Messenger RNA
14%
Multiple Myeloma
31%
Multivariate Analysis
13%
Non-Hodgkin Lymphoma
50%
Overall Survival
63%
Polyethylene Terephthalate
14%
Positron Emission Tomography
13%
Positron Emission Tomography-Computed Tomography
53%
Prognostic Factor
12%
Progression Free Survival
41%
Reduced Intensity Conditioning
27%
Rituximab
39%
Salvage Therapy
22%
Stem Cell Therapy
17%
T Cell
12%